MIP Immunotherapy for Cancer
Author Information
Author(s): Ahmad Faiz Mani, Jiju Kumar, Pawan Haridas, Seenu Upadhyay, Pramod Bhaskar Sangeeta
Primary Institution: National Institute of Immunology, New Delhi, India
Hypothesis
Can Mycobacterium indicus pranii (MIP) activate anti-tumor immune responses in tumor-bearing mice?
Conclusion
MIP therapy is effective in protecting mice from tumor by activating immune cells and reducing regulatory T cells.
Supporting Evidence
- MIP treatment delayed tumor growth and reduced tumor volume in mice.
- MIP-treated mice showed higher infiltration of immune cells in tumors.
- The percentage of regulatory T cells was lower in MIP-treated mice compared to controls.
- MIP therapy improved survival rates in tumor-bearing mice.
Takeaway
Researchers found that a treatment using a type of bacteria helped mice fight tumors better by boosting their immune system.
Methodology
B16F10 melanoma cells were injected into mice, and the effects of MIP treatment on tumor growth and immune response were evaluated.
Potential Biases
Potential bias in animal model selection and treatment administration.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
C57BL/6 mice, 6-8 weeks old.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website